We are live on ! Find out more
GTBP icon

GT Biopharma
GTBP

36 hedge funds and large institutions have $5.63M invested in GT Biopharma in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

29% more capital invested

Capital invested by funds: $4.36M → $5.63M (+$1.27M)

29% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 7

6% more funds holding

Funds holding: 34 → 36 (+2)

0.38% more ownership

Funds ownership: 0.27% → 0.65% (+0.38%)

Holders
36
Holders Change
+2
Holders Change %
+5.88%
% of All Funds
0.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
8
Reduced
6
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$5.64M
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$466K
3
BFS
Baskin Financial Services
Ontario, Canada
+$252K
4
Wells Fargo
Wells Fargo
California
+$167K
5
Renaissance Technologies
Renaissance Technologies
New York
+$76.9K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$44K
2
Millennium Management
Millennium Management
New York
-$36.8K
3
State Street
State Street
Massachusetts
-$34.8K
4
OQS
Occudo Quantitative Strategies
Florida
-$31K
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$26K
Name Holding Trade Value Shares
Change 		Change in
Stake
IA
26
IFP Advisors
Florida
$1K +$100 +2 New
TF
27
TimeScale Financial
Massachusetts
$966 – – –
BBPWM
28
Blue Bell Private Wealth Management
Pennsylvania
$266 – – –
CS
29
Credit Suisse
Switzerland
$157 – – –
ASN
30
Advisory Services Network
Georgia
$143 +$250 +5 New
Northwestern Mutual Wealth Management
31
Northwestern Mutual Wealth Management
Wisconsin
$136 +$250 +5 New
Bank of America
32
Bank of America
North Carolina
$64 +$100 +2 New
VF
33
Virtu Financial
New York
– -$44K -829 Closed
OQS
34
Occudo Quantitative Strategies
Florida
– -$31K -585 Closed
Qube Research & Technologies (QRT)
35
Qube Research & Technologies (QRT)
United Kingdom
– -$26K -496 Closed
SSA
36
Schonfeld Strategic Advisors
New York
– -$23K -437 Closed
BJL
37
Brighton Jones LLC
Washington
– -$21K -390 Closed
Commonwealth Equity Services
38
Commonwealth Equity Services
Massachusetts
– -$19K -372 Closed
Simplex Trading
39
Simplex Trading
Illinois
– -$1.2K -24 -73%
NA
40
NewEdge Advisors
Louisiana
– +$150 +3 New
1
2

GTBP Hedge Fund Activity: Q4 2022 in Review

36 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q4 2022, worth a combined $5.63M — up 29% from $4.36M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new GTBP positions and 7 closed out — a net gain of 2 holders — while 8 added to existing stakes and 6 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $5.64M. The largest seller was Virtu Financial, exiting entirely with an estimated $44K sold.

  • 36 institutional investors held GT Biopharma (GTBP) as of Q4 2022, up from 34 in Q3 2022.
  • Funds reported $5.63M of GT Biopharma stock for Q4 2022, up 29% quarter-over-quarter.
  • 9 funds opened new GT Biopharma positions in Q4 2022 and 7 closed out, a net change of +2 holders.
  • The largest GT Biopharma buyer in Q4 2022 was Armistice Capital, an estimated $5.64M added.
  • The largest GT Biopharma seller in Q4 2022 was Virtu Financial, an estimated $44K sold.

Based on aggregated 13F filings for Q4 2022.